References

1 Frykberg RG, Banks J. Challenges in the Treatment of Chronic Wounds. Adv Wound Care (New Rochelle). 2015;4(9):560-582. doi:10.1089/wound.2015.0635 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4528992/

2Feldman, R. (n.d.). Chronic wounds: Economic impact & costs to Medicare. Retrieved March 04, 2021, from https://www.woundcarestakeholders.org/news/studies-and-publications/chronic-wounds-economic-impact-costs-to-medicare#:~:text=Topline%20findings%20show%20that%20chronic,at%20%2428.1%20to%20%2431.7%20billion.

3Snyder RJ, Kasper MA, Patel K, Carter MJ, Kushnir I, Kushnir A, Serena TE. Safety and Efficacy of an Autologous Blood Clot Product in the Management of Texas 1A or 2A Neuropathic Diabetic Foot Ulcers: A Prospective, Multicenter, Open Label Pilot Study. Wounds. 2018 Jul;30(7):84-89. Epub 2018 Apr 20. PMID: 29718812. https://pubmed.ncbi.nlm.nih.gov/29718812/

4Serena TE, Kushnir I, Kushnir A, Yaakov RA, Eckert KA. The safety of an autologous whole blood clot product applied to full thickness der-mal wounds in a porcine model for up to 18 days. Chronic Wound Care Management and Research. 2019;6:39-49 https://doi.org/10.2147/CWCMR.S189836

crossmenu